Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Diversity considerations in HIV-1 vaccine selection.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B.

Science. 2002 Jun 28;296(5577):2354-60. Review.

PMID:
12089434
2.

Ancestral and consensus envelope immunogens for HIV-1 subtype C.

Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F, Haynes BF, Shaw GM, Korber BT, Hahn BH.

Virology. 2006 Sep 1;352(2):438-49. Epub 2006 Jun 14.

3.

Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity.

Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S161-8. Review.

PMID:
15285714
4.

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT.

Nat Med. 2007 Jan;13(1):100-6. Epub 2006 Dec 24.

PMID:
17187074
5.

Limitations of a molecular clock applied to considerations of the origin of HIV-1.

Korber B, Theiler J, Wolinsky S.

Science. 1998 Jun 19;280(5371):1868-71. No abstract available.

PMID:
9669945
6.

Consensus and ancestral state HIV vaccines.

Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, Rodrigo AG, Mullins JI.

Science. 2003 Mar 7;299(5612):1515-8; author reply 1515-8. No abstract available.

PMID:
12624248
7.

Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.

Barugahare B, Baker C, K'Aluoch O, Donovan R, Elrefaei M, Eggena M, Jones N, Mutalya S, Kityo C, Mugyenyi P, Cao H.

J Virol. 2005 Apr;79(7):4132-9.

8.

The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Wyatt R, Sodroski J.

Science. 1998 Jun 19;280(5371):1884-8. Review.

PMID:
9632381
10.

Epitope-vaccine as a new strategy against HIV-1 mutation.

Xiao Y, Lu Y, Chen YH.

Immunol Lett. 2001 May 1;77(1):3-6. Review.

PMID:
11348663
11.

Increasing genetic distance to HIV-1 subtype B and F1 consensus sequences in the Brazilian epidemic: a challenge for vaccine strategies based on central immunogens?

Bello G, GuimarĂ£es ML, Chequer-Fernandez SL, Eyer-Silva WA, Couto-Fernandez JC, Teixeira SL, Morgado MG.

Infect Genet Evol. 2007 Sep;7(5):594-9. Epub 2007 May 22.

PMID:
17574932
12.

Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.

Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, Sanders-Buell E, de Souza MS, Birx DL, McCutchan FE, Polonis VR.

J Virol. 2005 May;79(10):6089-101.

14.

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.

Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, Korioth-Schmitz B, Yu F, Rohne D, Martin KL, Miura A, Kong WP, Yang ZY, Gelman RS, Golubeva OG, Montefiori DC, Mascola JR, Nabel GJ.

J Virol. 2004 Jul;78(14):7490-7.

15.

Antiplatelet antibodies during the course of HIV-preventive vaccine trial.

Kaplan C, Morel-Kopp MC, Kieny MP, Kolbe H, Salmon P, Sicard D, Pialoux G, Meignier B, Excler JL, Plotkin S.

AIDS. 1996 Apr;10(4):447-9. No abstract available.

PMID:
8728055
16.

Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.

Hone DM, DeVico AL, Fouts TR, Onyabe DY, Agwale SM, Wambebe CO, Blattner WA, Gallo RC, Lewis GK.

J Hum Virol. 2002 Jan-Feb;5(1):17-23. Review.

PMID:
12352264
17.

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.

Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, Stamatatos L.

Virology. 2006 Jun 5;349(2):276-89. Epub 2006 Mar 9.

18.

Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.

Clarke DK, Cooper D, Egan MA, Hendry RM, Parks CL, Udem SA.

Springer Semin Immunopathol. 2006 Nov;28(3):239-53. Epub 2006 Sep 15. Review.

PMID:
16977404
19.

Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.

Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H, Robinson J, van der Groen G, Quinnan GV Jr.

Virology. 2006 Mar 30;347(1):36-51. Epub 2005 Dec 27.

20.

Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.

McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, Chesnut RW, Sette A, Essex M, Novitsky V, Newman MJ.

J Immunol. 2004 Aug 1;173(3):1941-50.

Supplemental Content

Support Center